Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

Next Previous
X
Search
Trial Profile

A Phase 2, 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lorecivivint (Primary)
  • Indications Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Biosplice Therapeutics; Samumed

    • Most Recent Events

    • 03 Jun 2023 Pooled analysis of two phase 2 trails (NCT02536833, NCT03122860) and two Phase 3 trials (NCT04385303, NCT03928184) presented at the 24th Annual Congress of the European League Against Rheumatism.
    • 14 Nov 2022 Post hoc pooled results presented at the ACR Convergence 2022.
    • 22 Jul 2021 According to a Biosplice Therapeutics media release, results of post hoc analysis from this study were published in the Rheumatology and Therapy.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top